MX2022006045A - Metodos de administracion de voxelotor. - Google Patents
Metodos de administracion de voxelotor.Info
- Publication number
- MX2022006045A MX2022006045A MX2022006045A MX2022006045A MX2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A
- Authority
- MX
- Mexico
- Prior art keywords
- voxelotor
- methods
- administering
- avoiding
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente métodos de uso de voxelotor para el tratamiento de la enfermedad de células falciformes en pacientes que también tienen insuficiencia hepática grave. También se proporcionan en la presente métodos para administrar voxelotor y evitar o disminuir las interacciones farmacológicas adversas con un inductor o inhibidor de CYP3A4. También se proporcionan en la presente métodos para evitar interacciones con voxelotor, un inhibidor moderado de CYP3A4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962937706P | 2019-11-19 | 2019-11-19 | |
US201962940154P | 2019-11-25 | 2019-11-25 | |
PCT/US2020/060923 WO2021101910A1 (en) | 2019-11-19 | 2020-11-17 | Methods of administering voxelotor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006045A true MX2022006045A (es) | 2022-08-15 |
Family
ID=73835728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006045A MX2022006045A (es) | 2019-11-19 | 2020-11-17 | Metodos de administracion de voxelotor. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230015823A1 (es) |
EP (1) | EP4061368A1 (es) |
BR (1) | BR112022009522A2 (es) |
CA (1) | CA3161761A1 (es) |
IL (1) | IL292982A (es) |
MX (1) | MX2022006045A (es) |
WO (1) | WO2021101910A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3237314A1 (en) * | 2021-11-05 | 2023-05-11 | Global Blood Therapeutics, Inc. | Methods of administering voxelotor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
BR112015032160B1 (pt) | 2014-02-07 | 2021-11-30 | Global Blood Therapeutics, Inc | Ansolvato cristalino de composto, composição e composição farmacêutica |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
-
2020
- 2020-11-17 CA CA3161761A patent/CA3161761A1/en active Pending
- 2020-11-17 WO PCT/US2020/060923 patent/WO2021101910A1/en unknown
- 2020-11-17 MX MX2022006045A patent/MX2022006045A/es unknown
- 2020-11-17 US US17/777,909 patent/US20230015823A1/en active Pending
- 2020-11-17 BR BR112022009522A patent/BR112022009522A2/pt unknown
- 2020-11-17 IL IL292982A patent/IL292982A/en unknown
- 2020-11-17 EP EP20824753.6A patent/EP4061368A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230015823A1 (en) | 2023-01-19 |
CA3161761A1 (en) | 2021-05-27 |
WO2021101910A1 (en) | 2021-05-27 |
BR112022009522A2 (pt) | 2022-08-16 |
IL292982A (en) | 2022-07-01 |
EP4061368A1 (en) | 2022-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
WO2018187698A3 (en) | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists | |
MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
MX2022006045A (es) | Metodos de administracion de voxelotor. | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
PH12018501790A1 (en) | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy | |
AU2017258649A1 (en) | Covalent BTK inhibitors and uses thereof | |
MX2022003945A (es) | Metodo para tratar vih con cabotegravir y rilpivirina. | |
CR20210029A (es) | MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA | |
WO2019014322A8 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES | |
MX2020000118A (es) | Composiciones y metodos para mejorar la funcion cardiaca. |